Skip to Main Content

Vedanta Biosciences is touting positive new Phase 2 results for a microbe-based treatment for C. difficile, the fourth major biotech to take this approach toward the life-threatening bacterial disease.

People who received a relatively high dose of Vedanta’s drug, which is made from eight strains of bacteria, had 80% fewer recurrences of C. diff than people who received a placebo, the company said Tuesday. The absolute difference in the proportion of people whose C. difficile infections recurred was more than 37 percentage points.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment